Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001082986 | SCV000262085 | benign | Alstrom syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000224355 | SCV000280857 | benign | not provided | 2015-06-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000424132 | SCV000532582 | benign | not specified | 2016-10-11 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Personalized Diabetes Medicine Program, |
RCV000445509 | SCV000536961 | benign | Monogenic diabetes | 2019-02-08 | criteria provided, single submitter | research | ACMG criteria: BA1 (5.6% in gnomAD African), BS2 (46 homozygotes in gnomAD), BP1 (most ALMS1 pathogenic variants are truncating) REVEL score 0.2 + PP3 (4 predictors) + BP4 (5 predictors)= conflicting evidence, not using)= benign |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000424132 | SCV000864084 | benign | not specified | 2016-02-15 | criteria provided, single submitter | clinical testing | Variant summary: ALMS1 c.671C>A (alternative name c.674C>A) affects a conserved nucleotide, resulting in amino acid change from Pro to His. 3/4 in-silico tools predict this variant to be damaging (SNPs&GO not captured due to low reliability index), however, these predictions have not been validated through in vitro/vivo functional studies yet. This variant was found in 658/122504 control chromosomes from ExAC dataset at a frequency of 0.0053713, predominantly in individuals of African descent (0.05675) including 18 homozygotes. This frequency exceeds the maximal expected frequency of a pathogenic allele (0.0022361), suggesting this variant is benign ethnic-specific polymorphism. This variant, to our knowledge, has not been reported in affected individuals via publications. One clinical laboratory (via ClinVar) classified this variant as benign, without evidence to independently evaluate. Taken together, this variant was classified as benign. |
Laboratory for Molecular Medicine, |
RCV000424132 | SCV000967040 | benign | not specified | 2016-03-21 | criteria provided, single submitter | clinical testing | p.Pro224His in exon 4 of ALMS1: This variant is not expected to have clinical si gnificance because it has been identified in 5.67% (556/9798) of African chromos omes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs11889925). |
Athena Diagnostics | RCV000224355 | SCV001143005 | benign | not provided | 2019-03-21 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV001082986 | SCV002605237 | likely risk allele | Alstrom syndrome | 2024-02-15 | criteria provided, single submitter | research | Potent mutations in ALMS1 are associated with a rare condition called Alstrom syndrome. It can cause excessive eating, insulin resistance. However, no evidence is found to ascertain the role of rs11889925 in Alstrom syndrome yet.This variant is a potent moderate impact, deleterious variant with a CADD score of 25.2. This gene is found to be frequently associated with Alstrom syndrome as per recent evidence as well, with sufficient scientific evidence to support the reported classification. |
Ambry Genetics | RCV002363032 | SCV002663606 | benign | Cardiovascular phenotype | 2019-01-07 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
ARUP Laboratories, |
RCV001082986 | SCV004563999 | benign | Alstrom syndrome | 2023-09-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001082986 | SCV001457869 | benign | Alstrom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000224355 | SCV001799888 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000424132 | SCV001929735 | benign | not specified | no assertion criteria provided | clinical testing |